In a more recent study Rye and coworkers have analyzed gene signatures in a group of prostate cancer patients and showed the existence of only two groups of tumors: the poor prognosis group was characterized by enrichment in embryonic stem cell, ERG-fusion, and MYC-rich signatures; the other group was associated with good prognosis [346]. This evidence concerns the gene MYC and prostate cancer.